Introduction to the NULISAseq Mouse Panel 120
Alamar Biosciences is making headlines with its latest innovation, the NULISAseq Mouse Panel 120. This sophisticated biomarker profiling solution represents a leap forward in the realm of protein analyses for pre-clinical research.
Breakthrough in Protein Biomarker Analysis
Alamar Biosciences is committed to powering precision proteomics that enhance the early detection of diseases. The NULISAseq Mouse Panel 120 is designed to provide extensive coverage of protein targets for expression analysis specifically in mouse models. This comprehensive panel allows researchers to analyze 120 proteins that play vital roles in significant biological pathways related to inflammation, neurodegeneration, and immuno-oncology.
Empowering Researchers
Dr. Yuling Luo, the Founder, Chairman, and CEO of Alamar Biosciences, emphasized the significance of this innovative panel, stating that it encompasses an exceptional selection of proteins vital for investigating crucial biological pathways in pre-clinical models.
Unique Features of the NULISAseq Mouse Panel 120
One standout feature of the NULISAseq Mouse Panel 120 is its distinct focus on neurological content. This is particularly important for researchers focused on neurodegenerative diseases and the effects of potential treatments. Dr. Cheryl Wellington, a professor at the University of British Columbia, expressed her enthusiasm about incorporating the NULISAseq Mouse Panel 120 into her research, highlighting its potential to provide new insights into the mechanisms of diseases like dementia and traumatic brain injuries.
Advanced Technology Behind the Panel
Built on cutting-edge multiplexing technology, the NULISAseq Mouse Panel 120 offers high sensitivity and high throughput capabilities that help uncover complex biological mechanisms. This remarkable panel features attomolar (fg/ml) sensitivity and an impressive dynamic range of ten logs, allowing for the detection of a broad array of proteins present in mouse plasma. Researchers can obtain meaningful data, even from low-abundance proteins like p-tau217, using as little as 5 µl of sample input.
Alamar Biosciences and Its Mission
Alamar Biosciences operates with a clear vision: to empower precision proteomics that fosters early disease detection. The NULISA™ Platform and ARGO™ HT System work in tandem with the latest genomics advancements, achieving unparalleled detection sensitivity far surpassing existing protein detection technologies. These innovations promise to significantly benefit life sciences research.
Conclusion
The launch of the NULISAseq Mouse Panel 120 marks a significant milestone for Alamar Biosciences, solidifying its place as a leader in precision proteomics. As researchers continue to explore complex biological questions, this advanced panel will provide the support they need to uncover critical insights into disease mechanisms and therapeutic effectiveness.
Frequently Asked Questions
What is the NULISAseq Mouse Panel 120?
The NULISAseq Mouse Panel 120 is a biomarker profiling solution designed by Alamar Biosciences, which analyzes 120 proteins for pre-clinical research.
What diseases can the panel help study?
This panel provides comprehensive coverage of key pathways related to inflammation, neurodegeneration, and immuno-oncology, thus aiding research into these diseases.
Who can benefit from using the NULISAseq Mouse Panel 120?
Researchers in the fields of biomedical science and drug development can benefit significantly by using this panel in their studies.
What technology does the NULISAseq Mouse Panel 120 utilize?
The panel utilizes advanced multiplexing technology, providing high sensitivity and a wide dynamic range for protein detection.
How does Alamar Biosciences contribute to disease detection?
Alamar Biosciences is committed to precision proteomics to enable early detection of diseases, integrating advanced technologies within its research frameworks.
